These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 25036404)

  • 1. The impact of TP53 and RAS mutations on cerebellar glioblastomas.
    Milinkovic VP; Skender Gazibara MK; Manojlovic Gacic EM; Gazibara TM; Tanic NT
    Exp Mol Pathol; 2014 Oct; 97(2):202-7. PubMed ID: 25036404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies.
    Russo A; Bazan V; Agnese V; Rodolico V; Gebbia N
    Ann Oncol; 2005 May; 16 Suppl 4():iv44-49. PubMed ID: 15923428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
    Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
    Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer.
    Ouerhani S; Elgaaied AB
    Cancer Biomark; 2011-2012; 10(6):259-66. PubMed ID: 22820081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study.
    Bazan V; Agnese V; Corsale S; Calò V; Valerio MR; Latteri MA; Vieni S; Grassi N; Cicero G; Dardanoni G; Tomasino RM; Colucci G; Gebbia N; Russo A;
    Ann Oncol; 2005 May; 16 Suppl 4():iv50-55. PubMed ID: 15923430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of survival between cerebellar and supratentorial glioblastoma patients: surveillance, epidemiology, and end results (SEER) analysis.
    Jeswani S; Nuño M; Folkerts V; Mukherjee D; Black KL; Patil CG
    Neurosurgery; 2013 Aug; 73(2):240-6; discussion 246; quiz 246. PubMed ID: 23615082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma.
    Duldulao MP; Lee W; Nelson RA; Li W; Chen Z; Kim J; Garcia-Aguilar J
    Ann Surg Oncol; 2013 Jul; 20(7):2166-71. PubMed ID: 23456389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RAS, BRAF, and TP53 gene mutations in Taiwanese colorectal cancer patients.
    Chang YS; Chang SJ; Yeh KT; Lin TH; Chang JG
    Onkologie; 2013; 36(12):719-24. PubMed ID: 24356563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma.
    Janzarik WG; Kratz CP; Loges NT; Olbrich H; Klein C; Schäfer T; Scheurlen W; Roggendorf W; Weiller C; Niemeyer C; Korinthenberg R; Pfister S; Omran H
    Neuropediatrics; 2007 Apr; 38(2):61-3. PubMed ID: 17712732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 and p21/Waf1 protein expression and K-ras codon 12 mutation in carcinoma of the papilla of Vater.
    Zhao B; Kimura W; Futakawa N; Muto T; Kubota K; Harihara Y; Takayama T; Makuuchi M
    Am J Gastroenterol; 1999 Aug; 94(8):2128-34. PubMed ID: 10445539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIK3CA, HRAS and KRAS gene mutations in human penile cancer.
    Andersson P; Kolaric A; Windahl T; Kirrander P; Söderkvist P; Karlsson MG
    J Urol; 2008 May; 179(5):2030-4. PubMed ID: 18355852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human germline and somatic cells have similar TP53 and Kirsten-RAS gene single base mutation frequencies.
    Cole DN; Carlson JA; Wilson VL
    Environ Mol Mutagen; 2008 Jul; 49(6):417-25. PubMed ID: 18418864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.
    Side LE; Curtiss NP; Teel K; Kratz C; Wang PW; Larson RA; Le Beau MM; Shannon KM
    Genes Chromosomes Cancer; 2004 Mar; 39(3):217-23. PubMed ID: 14732923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The presence of telomere fusion in sporadic colon cancer independently of disease stage, TP53/KRAS mutation status, mean telomere length, and telomerase activity.
    Tanaka H; Beam MJ; Caruana K
    Neoplasia; 2014 Oct; 16(10):814-23. PubMed ID: 25379018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS and TP53 mutations in bronchoscopy samples from former lung cancer patients.
    Gao W; Jin J; Yin J; Land S; Gaither-Davis A; Christie N; Luketich JD; Siegfried JM; Keohavong P
    Mol Carcinog; 2017 Feb; 56(2):381-388. PubMed ID: 27182622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.
    Arnault JP; Mateus C; Escudier B; Tomasic G; Wechsler J; Hollville E; Soria JC; Malka D; Sarasin A; Larcher M; André J; Kamsu-Kom N; Boussemart L; Lacroix L; Spatz A; Eggermont AM; Druillennec S; Vagner S; Eychène A; Dumaz N; Robert C
    Clin Cancer Res; 2012 Jan; 18(1):263-72. PubMed ID: 22096025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single base instability is promoted in vulvar lichen sclerosus.
    Tapp RA; Feng J; Jones JW; Carlson JA; Wilson VL
    J Invest Dermatol; 2007 Nov; 127(11):2563-76. PubMed ID: 17554370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High incidence of MGMT promoter methylation in primary glioblastomas without correlation with TP53 gene mutations.
    Jesien-Lewandowicz E; Jesionek-Kupnicka D; Zawlik I; Szybka M; Kulczycka-Wojdala D; Rieske P; Sieruta M; Jaskolski D; Och W; Skowronski W; Sikorska B; Potemski P; Papierz W; Liberski PP; Kordek R
    Cancer Genet Cytogenet; 2009 Jan; 188(2):77-82. PubMed ID: 19100509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a rapid and practical mutation screening assay for human lung adenocarcinoma.
    Choi H; Kratz J; Pham P; Lee S; Ray R; Kwon YW; Mao JH; Kang HC; Jablons D; Kim IJ
    Int J Oncol; 2012 Jun; 40(6):1900-6. PubMed ID: 22407457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.